Breast Cancer Clinical Trials in Baltimore

Showing 81-100 of 400 trials

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05455658

This phase II trial studies the effect of DNA plasmid based vaccine (STEMVAC) in treating patients with patients with stage IB-III triple negative breast cancer. STEMVAC may wake up the immune system in patients who have had a diagnosis of triple negative breast cancer and have been treated. STEMVAC targets proteins that are expressed on breast cancer cells and works by boosting the immune system to recognize and destroy the invader cancer cell proteins that are causing the disease. The purpose of this trial is to test the immune system's response to STEMVAC.

Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8+14 more

University of Washington33 participantsStarted Nov 2022

Baltimore, Maryland, United States • Seattle, Washington, United States • Madison, Wisconsin, United States

ACTIVE_NOT_RECRUITINGPHASE2< 1 mile

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Invasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7+1 more

National Cancer Institute (NCI)67 participantsStarted Aug 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +11 more locations

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Breast Cancer Trials in Other Cities

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

CARE (Chemotherapy Alopecia REduction)

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Other Conditions in Baltimore